MRKMerck Sharp & Dohme LLCRunning, no new patients
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
High-risk Non-muscle Invasive Bladder Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 1,397 (planned)
- Started
- Dec 24, 2018
- Main results expected
- Jul 31, 2028
- Fully finished
- Nov 20, 2034
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Complete Response Rate (CRR) by Blinded Independent Central Review (BICR) (Cohort A)
Measured over: Up to ~3.5 years
Event-Free Survival (EFS) (Cohort B)
Measured over: Up to ~5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03711032 · record last updated 2026-10-23 · checked 2026-11-09 15:47 UTC